Thank you very much, Mr. Chair, and thank you to our witnesses for being here today. It's always good to see you.
I have a few questions. Hopefully, I'll have time to get them all in.
Ms. Salmon, one of your comments was about the business risks, that the whole first foray into closed containment was all about managing the risks. One of them was with respect to the disease aspect of it. We've recently engaged in some debate on ISA, and we had some of that challenge in Atlantic Canada at one time.
I would like to know your perspective on that issue at this point in time, that is, the perspective of your producers. Maybe more specifically, what are some of the things you're doing right now to protect against that or what are some of your action plans regarding ISA?